BioAge Beats IPO Investor Lawsuit Over Weight Loss Trial End (1)

BioAge Labs Inc. defeated investor allegations it concealed risks of elevated liver enzymes, a potential sign of damage, in a weight-loss drug trial during its initial public offering.

The shareholder leading the case didn’t point to any statement in the IPO documents that was misleading without disclosing the risk heightened liver enzymes, transaminitis, posed to the drug trial, Chief Judge Richard Seeborg said Thursday. The Southeastern Pennsylvania Transportation Authority needed to do more than allege the risk of transaminitis was inevitable or that disclosures were misleading without discussing it.

“That can only be true if the risk disclosures’ failure to ...